Acadia Pharmaceuticals | Beneficio Operativo



Operating Profit Cambio Fecha
Acadia Pharmaceuticals USD 153.5M 121.86M 2024-12
ALKERMES USD 162.69M 57.93M 2024-12
Alnylam Pharmaceuticals USD -105159000 28.25M 2024-12
Biogen USD 441.4M 24.4M 2024-12
BioMarin Pharmaceutical USD 161.41M 47.51M 2024-12
Bristol-Myers Squibb USD 793M 1.39B 2024-12
Corcept Therapeutics USD 25.26M 21.34M 2024-12
Cytokinetics USD -139040000 1.76M 2024-12
Eisai JPY 27.56B 13.14B 2024-12
Eli Lilly USD 5.15B 3.62B 2024-12
Incyte USD 301.51M 155.43M 2024-12
Intra Cellular Therapies USD -29197000 9.65M 2024-12
J&J USD 3.89B 549M 2024-12
Moderna USD -1246000000 1.18B 2024-12
Neurocrine Biosciences USD 142M 41.8M 2024-12
Pfizer USD -409000000 5.57B 2024-12
Prothena USD -64897000 1.62M 2024-12
PTC Therapeutics USD -62489000 7.98M 2024-12
Sarepta Therapeutics USD 161.68M 139.48M 2024-12
Ultragenyx Pharmaceutical USD -122278000 9.71M 2024-12
Vertex Pharmaceuticals USD 1.03B 90.3M 2024-12



Acadia Pharmaceuticals Beneficio Operativo - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.